ILAb Co., Ltd.
- Biotech or pharma, therapeutic R&D
Small molecule immunotherapeutics Company: Biologics to Chemical
ILAb has been focusing on the discovery and development of first-in-class small molecules for well-validated immune targets to provide competitive alternatives over highly-priced, painful injectable biologic products on the market for the treatment of inflammatory diseases and cancers.
[Out-licensing Opportunities]
Oral TNF selective Inihbitor for inflammatory diseases in Phase 1b stage
Oral PD-L1 inhibitor for oncology indications in pre-clinical stage
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}